nodes	percent_of_prediction	percent_of_DWPC	metapath
Thioridazine—HTR7—vein—ovarian cancer	0.0288	0.144	CbGeAlD
Thioridazine—HTR2A—vein—ovarian cancer	0.018	0.0896	CbGeAlD
Thioridazine—Menstruation irregular—Docetaxel—ovarian cancer	0.00735	0.0106	CcSEcCtD
Thioridazine—Systemic lupus erythematosus—Docetaxel—ovarian cancer	0.00735	0.0106	CcSEcCtD
Thioridazine—Aplastic anaemia—Vinorelbine—ovarian cancer	0.0067	0.00965	CcSEcCtD
Thioridazine—Eruption—Docetaxel—ovarian cancer	0.00662	0.00953	CcSEcCtD
Thioridazine—Lethargy—Topotecan—ovarian cancer	0.00618	0.0089	CcSEcCtD
Thioridazine—Vomiting—Altretamine—ovarian cancer	0.00598	0.00862	CcSEcCtD
Thioridazine—Cardiac arrest—Topotecan—ovarian cancer	0.00576	0.0083	CcSEcCtD
Thioridazine—Blood disorder—Paclitaxel—ovarian cancer	0.00575	0.00828	CcSEcCtD
Thioridazine—Cardiac arrest—Melphalan—ovarian cancer	0.00564	0.00812	CcSEcCtD
Thioridazine—Nausea—Altretamine—ovarian cancer	0.00559	0.00805	CcSEcCtD
Thioridazine—Pancytopenia—Chlorambucil—ovarian cancer	0.00559	0.00804	CcSEcCtD
Thioridazine—Lethargy—Vinorelbine—ovarian cancer	0.00529	0.00762	CcSEcCtD
Thioridazine—KCNH2—myometrium—ovarian cancer	0.00528	0.0263	CbGeAlD
Thioridazine—Hepatotoxicity—Docetaxel—ovarian cancer	0.00527	0.00759	CcSEcCtD
Thioridazine—Body temperature increased—Carboplatin—ovarian cancer	0.00514	0.0074	CcSEcCtD
Thioridazine—Jaundice—Chlorambucil—ovarian cancer	0.00511	0.00736	CcSEcCtD
Thioridazine—Pancytopenia—Topotecan—ovarian cancer	0.00497	0.00716	CcSEcCtD
Thioridazine—Pancytopenia—Melphalan—ovarian cancer	0.00487	0.00701	CcSEcCtD
Thioridazine—Ventricular tachycardia—Paclitaxel—ovarian cancer	0.0048	0.00692	CcSEcCtD
Thioridazine—Weight increased—Topotecan—ovarian cancer	0.00477	0.00686	CcSEcCtD
Thioridazine—Amenorrhoea—Docetaxel—ovarian cancer	0.00463	0.00667	CcSEcCtD
Thioridazine—Eruption—Epirubicin—ovarian cancer	0.00446	0.00643	CcSEcCtD
Thioridazine—Jaundice—Melphalan—ovarian cancer	0.00446	0.00642	CcSEcCtD
Thioridazine—HTR7—epithelium—ovarian cancer	0.00445	0.0222	CbGeAlD
Thioridazine—ADRA1A—epithelium—ovarian cancer	0.00429	0.0214	CbGeAlD
Thioridazine—Pancytopenia—Vinorelbine—ovarian cancer	0.00425	0.00613	CcSEcCtD
Thioridazine—HRH1—myometrium—ovarian cancer	0.00423	0.0211	CbGeAlD
Thioridazine—ADRA2A—myometrium—ovarian cancer	0.00415	0.0207	CbGeAlD
Thioridazine—Eruption—Doxorubicin—ovarian cancer	0.00413	0.00595	CcSEcCtD
Thioridazine—KCNH2—uterine cervix—ovarian cancer	0.00411	0.0205	CbGeAlD
Thioridazine—HTR2C—female reproductive system—ovarian cancer	0.00411	0.0205	CbGeAlD
Thioridazine—Tremor—Chlorambucil—ovarian cancer	0.00384	0.00553	CcSEcCtD
Thioridazine—Nasal congestion—Paclitaxel—ovarian cancer	0.00383	0.00551	CcSEcCtD
Thioridazine—Anaemia—Chlorambucil—ovarian cancer	0.00379	0.00546	CcSEcCtD
Thioridazine—Agitation—Chlorambucil—ovarian cancer	0.00377	0.00542	CcSEcCtD
Thioridazine—Angioedema—Chlorambucil—ovarian cancer	0.00374	0.00539	CcSEcCtD
Thioridazine—Agranulocytosis—Vinorelbine—ovarian cancer	0.00373	0.00537	CcSEcCtD
Thioridazine—KCNH2—endometrium—ovarian cancer	0.00371	0.0185	CbGeAlD
Thioridazine—Ventricular arrhythmia—Epirubicin—ovarian cancer	0.00371	0.00534	CcSEcCtD
Thioridazine—HTR7—gonad—ovarian cancer	0.0037	0.0185	CbGeAlD
Thioridazine—Dermatitis exfoliative—Paclitaxel—ovarian cancer	0.00369	0.00532	CcSEcCtD
Thioridazine—Leukopenia—Chlorambucil—ovarian cancer	0.00367	0.00528	CcSEcCtD
Thioridazine—Arrhythmia—Melphalan—ovarian cancer	0.00367	0.00528	CcSEcCtD
Thioridazine—Lethargy—Paclitaxel—ovarian cancer	0.00356	0.00512	CcSEcCtD
Thioridazine—Ventricular arrhythmia—Doxorubicin—ovarian cancer	0.00343	0.00494	CcSEcCtD
Thioridazine—KCNH2—uterus—ovarian cancer	0.00342	0.0171	CbGeAlD
Thioridazine—CYP2C8—endometrium—ovarian cancer	0.0034	0.017	CbGeAlD
Thioridazine—HTR2A—embryo—ovarian cancer	0.0034	0.017	CbGeAlD
Thioridazine—Confusional state—Chlorambucil—ovarian cancer	0.00337	0.00486	CcSEcCtD
Thioridazine—Anaemia—Topotecan—ovarian cancer	0.00337	0.00486	CcSEcCtD
Thioridazine—Angioedema—Topotecan—ovarian cancer	0.00333	0.0048	CcSEcCtD
Thioridazine—HRH1—epithelium—ovarian cancer	0.00332	0.0166	CbGeAlD
Thioridazine—Cardiac arrest—Paclitaxel—ovarian cancer	0.00331	0.00477	CcSEcCtD
Thioridazine—HTR7—female reproductive system—ovarian cancer	0.0033	0.0165	CbGeAlD
Thioridazine—Anaemia—Melphalan—ovarian cancer	0.0033	0.00476	CcSEcCtD
Thioridazine—HRH1—uterine cervix—ovarian cancer	0.00329	0.0164	CbGeAlD
Thioridazine—Blood disorder—Epirubicin—ovarian cancer	0.00329	0.00473	CcSEcCtD
Thioridazine—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00327	0.00472	CcSEcCtD
Thioridazine—Leukopenia—Topotecan—ovarian cancer	0.00327	0.0047	CcSEcCtD
Thioridazine—ADRA2A—uterine cervix—ovarian cancer	0.00323	0.0161	CbGeAlD
Thioridazine—Arrhythmia—Vinorelbine—ovarian cancer	0.0032	0.00461	CcSEcCtD
Thioridazine—Leukopenia—Melphalan—ovarian cancer	0.0032	0.00461	CcSEcCtD
Thioridazine—Anorexia—Chlorambucil—ovarian cancer	0.00319	0.00459	CcSEcCtD
Thioridazine—HRH1—decidua—ovarian cancer	0.00314	0.0157	CbGeAlD
Thioridazine—Amenorrhoea—Epirubicin—ovarian cancer	0.00312	0.0045	CcSEcCtD
Thioridazine—Erythema—Vinorelbine—ovarian cancer	0.00312	0.0045	CcSEcCtD
Thioridazine—ADRA2A—decidua—ovarian cancer	0.00308	0.0154	CbGeAlD
Thioridazine—KCNH2—female reproductive system—ovarian cancer	0.00308	0.0154	CbGeAlD
Thioridazine—Blood disorder—Doxorubicin—ovarian cancer	0.00304	0.00438	CcSEcCtD
Thioridazine—Lethargy—Docetaxel—ovarian cancer	0.00302	0.00434	CcSEcCtD
Thioridazine—HRH1—endometrium—ovarian cancer	0.00298	0.0149	CbGeAlD
Thioridazine—Sweating increased—Paclitaxel—ovarian cancer	0.00293	0.00423	CcSEcCtD
Thioridazine—ADRA2A—endometrium—ovarian cancer	0.00292	0.0146	CbGeAlD
Thioridazine—CYP2C19—vagina—ovarian cancer	0.00292	0.0146	CbGeAlD
Thioridazine—Oedema—Melphalan—ovarian cancer	0.00292	0.0042	CcSEcCtD
Thioridazine—Thrombocytopenia—Topotecan—ovarian cancer	0.00292	0.0042	CcSEcCtD
Thioridazine—Decreased appetite—Chlorambucil—ovarian cancer	0.00291	0.00419	CcSEcCtD
Thioridazine—KCNH2—bone marrow—ovarian cancer	0.0029	0.0145	CbGeAlD
Thioridazine—Amenorrhoea—Doxorubicin—ovarian cancer	0.00289	0.00416	CcSEcCtD
Thioridazine—Anaemia—Vinorelbine—ovarian cancer	0.00288	0.00415	CcSEcCtD
Thioridazine—Hyperhidrosis—Topotecan—ovarian cancer	0.00288	0.00415	CcSEcCtD
Thioridazine—Pancytopenia—Paclitaxel—ovarian cancer	0.00286	0.00412	CcSEcCtD
Thioridazine—Thrombocytopenia—Melphalan—ovarian cancer	0.00285	0.00411	CcSEcCtD
Thioridazine—Angioedema—Vinorelbine—ovarian cancer	0.00285	0.00411	CcSEcCtD
Thioridazine—Tachycardia—Melphalan—ovarian cancer	0.00285	0.0041	CcSEcCtD
Thioridazine—Anorexia—Topotecan—ovarian cancer	0.00284	0.00409	CcSEcCtD
Thioridazine—CYP2C8—female reproductive system—ovarian cancer	0.00282	0.014	CbGeAlD
Thioridazine—KCNH2—female gonad—ovarian cancer	0.0028	0.014	CbGeAlD
Thioridazine—Leukopenia—Vinorelbine—ovarian cancer	0.00279	0.00402	CcSEcCtD
Thioridazine—KCNH2—vagina—ovarian cancer	0.00278	0.0139	CbGeAlD
Thioridazine—Anorexia—Melphalan—ovarian cancer	0.00278	0.004	CcSEcCtD
Thioridazine—HTR2A—epithelium—ovarian cancer	0.00277	0.0138	CbGeAlD
Thioridazine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00276	0.00397	CcSEcCtD
Thioridazine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00275	0.00396	CcSEcCtD
Thioridazine—Ventricular tachycardia—Epirubicin—ovarian cancer	0.00275	0.00395	CcSEcCtD
Thioridazine—Weight increased—Paclitaxel—ovarian cancer	0.00274	0.00395	CcSEcCtD
Thioridazine—Hypotension—Melphalan—ovarian cancer	0.00272	0.00392	CcSEcCtD
Thioridazine—Abnormal dreams—Epirubicin—ovarian cancer	0.00271	0.00391	CcSEcCtD
Thioridazine—Dermatitis contact—Epirubicin—ovarian cancer	0.00271	0.00391	CcSEcCtD
Thioridazine—ADRA2A—gonad—ovarian cancer	0.00271	0.0135	CbGeAlD
Thioridazine—ADRA2A—uterus—ovarian cancer	0.00269	0.0134	CbGeAlD
Thioridazine—HTR7—testis—ovarian cancer	0.00267	0.0133	CbGeAlD
Thioridazine—Body temperature increased—Chlorambucil—ovarian cancer	0.00264	0.00381	CcSEcCtD
Thioridazine—Decreased appetite—Topotecan—ovarian cancer	0.00259	0.00373	CcSEcCtD
Thioridazine—Aplastic anaemia—Epirubicin—ovarian cancer	0.00258	0.00371	CcSEcCtD
Thioridazine—Constipation—Topotecan—ovarian cancer	0.00255	0.00367	CcSEcCtD
Thioridazine—CYP2C8—vagina—ovarian cancer	0.00255	0.0127	CbGeAlD
Thioridazine—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.00254	0.00366	CcSEcCtD
Thioridazine—Decreased appetite—Melphalan—ovarian cancer	0.00253	0.00365	CcSEcCtD
Thioridazine—DRD2—testis—ovarian cancer	0.00252	0.0126	CbGeAlD
Thioridazine—Dermatitis contact—Doxorubicin—ovarian cancer	0.00251	0.00362	CcSEcCtD
Thioridazine—Abnormal dreams—Doxorubicin—ovarian cancer	0.00251	0.00362	CcSEcCtD
Thioridazine—CYP2C9—female reproductive system—ovarian cancer	0.0025	0.0125	CbGeAlD
Thioridazine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00249	0.00359	CcSEcCtD
Thioridazine—Tachycardia—Vinorelbine—ovarian cancer	0.00249	0.00358	CcSEcCtD
Thioridazine—KCNH2—testis—ovarian cancer	0.00248	0.0124	CbGeAlD
Thioridazine—HRH1—female reproductive system—ovarian cancer	0.00247	0.0123	CbGeAlD
Thioridazine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00246	0.00355	CcSEcCtD
Thioridazine—Feeling abnormal—Topotecan—ovarian cancer	0.00245	0.00353	CcSEcCtD
Thioridazine—Anorexia—Vinorelbine—ovarian cancer	0.00243	0.0035	CcSEcCtD
Thioridazine—Pancytopenia—Docetaxel—ovarian cancer	0.00243	0.00349	CcSEcCtD
Thioridazine—ADRA2A—female reproductive system—ovarian cancer	0.00242	0.0121	CbGeAlD
Thioridazine—Aplastic anaemia—Doxorubicin—ovarian cancer	0.00238	0.00343	CcSEcCtD
Thioridazine—Hypotension—Vinorelbine—ovarian cancer	0.00238	0.00343	CcSEcCtD
Thioridazine—Oedema peripheral—Paclitaxel—ovarian cancer	0.00238	0.00342	CcSEcCtD
Thioridazine—CYP2E1—female reproductive system—ovarian cancer	0.00237	0.0118	CbGeAlD
Thioridazine—Body temperature increased—Topotecan—ovarian cancer	0.00235	0.00339	CcSEcCtD
Thioridazine—Weight increased—Docetaxel—ovarian cancer	0.00232	0.00335	CcSEcCtD
Thioridazine—HTR2A—gonad—ovarian cancer	0.00231	0.0115	CbGeAlD
Thioridazine—Diarrhoea—Chlorambucil—ovarian cancer	0.00229	0.0033	CcSEcCtD
Thioridazine—CYP2C8—testis—ovarian cancer	0.00227	0.0113	CbGeAlD
Thioridazine—Photosensitivity—Epirubicin—ovarian cancer	0.00227	0.00327	CcSEcCtD
Thioridazine—HRH1—female gonad—ovarian cancer	0.00224	0.0112	CbGeAlD
Thioridazine—HRH1—vagina—ovarian cancer	0.00223	0.0111	CbGeAlD
Thioridazine—Jaundice—Docetaxel—ovarian cancer	0.00222	0.0032	CcSEcCtD
Thioridazine—Decreased appetite—Vinorelbine—ovarian cancer	0.00221	0.00319	CcSEcCtD
Thioridazine—ADRA2A—female gonad—ovarian cancer	0.0022	0.011	CbGeAlD
Thioridazine—Hypersensitivity—Topotecan—ovarian cancer	0.00219	0.00316	CcSEcCtD
Thioridazine—ADRA2A—vagina—ovarian cancer	0.00219	0.0109	CbGeAlD
Thioridazine—Constipation—Vinorelbine—ovarian cancer	0.00218	0.00314	CcSEcCtD
Thioridazine—Arrhythmia—Paclitaxel—ovarian cancer	0.00215	0.0031	CcSEcCtD
Thioridazine—Hypersensitivity—Melphalan—ovarian cancer	0.00215	0.00309	CcSEcCtD
Thioridazine—Vomiting—Chlorambucil—ovarian cancer	0.00213	0.00306	CcSEcCtD
Thioridazine—Agranulocytosis—Docetaxel—ovarian cancer	0.00212	0.00306	CcSEcCtD
Thioridazine—Mental disorder—Paclitaxel—ovarian cancer	0.00211	0.00304	CcSEcCtD
Thioridazine—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.00211	0.00304	CcSEcCtD
Thioridazine—Photosensitivity—Doxorubicin—ovarian cancer	0.0021	0.00302	CcSEcCtD
Thioridazine—Erythema—Paclitaxel—ovarian cancer	0.0021	0.00302	CcSEcCtD
Thioridazine—Feeling abnormal—Vinorelbine—ovarian cancer	0.0021	0.00302	CcSEcCtD
Thioridazine—HTR2A—female reproductive system—ovarian cancer	0.00206	0.0103	CbGeAlD
Thioridazine—Diarrhoea—Topotecan—ovarian cancer	0.00204	0.00293	CcSEcCtD
Thioridazine—Lethargy—Epirubicin—ovarian cancer	0.00203	0.00293	CcSEcCtD
Thioridazine—Body temperature increased—Vinorelbine—ovarian cancer	0.00201	0.0029	CcSEcCtD
Thioridazine—Oedema peripheral—Docetaxel—ovarian cancer	0.00201	0.0029	CcSEcCtD
Thioridazine—Diarrhoea—Melphalan—ovarian cancer	0.00199	0.00287	CcSEcCtD
Thioridazine—HRH1—testis—ovarian cancer	0.00199	0.00993	CbGeAlD
Thioridazine—Nausea—Chlorambucil—ovarian cancer	0.00199	0.00286	CcSEcCtD
Thioridazine—Vision blurred—Paclitaxel—ovarian cancer	0.00198	0.00285	CcSEcCtD
Thioridazine—Tremor—Paclitaxel—ovarian cancer	0.00197	0.00283	CcSEcCtD
Thioridazine—ADRA2A—testis—ovarian cancer	0.00195	0.00976	CbGeAlD
Thioridazine—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.00195	0.00281	CcSEcCtD
Thioridazine—Anaemia—Paclitaxel—ovarian cancer	0.00194	0.00279	CcSEcCtD
Thioridazine—Agitation—Paclitaxel—ovarian cancer	0.00193	0.00278	CcSEcCtD
Thioridazine—Angioedema—Paclitaxel—ovarian cancer	0.00192	0.00276	CcSEcCtD
Thioridazine—CYP2E1—testis—ovarian cancer	0.00191	0.00954	CbGeAlD
Thioridazine—Cardiac arrest—Epirubicin—ovarian cancer	0.00189	0.00273	CcSEcCtD
Thioridazine—Vomiting—Topotecan—ovarian cancer	0.00189	0.00273	CcSEcCtD
Thioridazine—Lethargy—Doxorubicin—ovarian cancer	0.00188	0.00271	CcSEcCtD
Thioridazine—Leukopenia—Paclitaxel—ovarian cancer	0.00188	0.00271	CcSEcCtD
Thioridazine—Rash—Topotecan—ovarian cancer	0.00188	0.0027	CcSEcCtD
Thioridazine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00188	0.0027	CcSEcCtD
Thioridazine—CYP2D6—female reproductive system—ovarian cancer	0.00188	0.00936	CbGeAlD
Thioridazine—Dermatitis—Topotecan—ovarian cancer	0.00188	0.0027	CcSEcCtD
Thioridazine—Headache—Topotecan—ovarian cancer	0.00187	0.00269	CcSEcCtD
Thioridazine—HTR2A—vagina—ovarian cancer	0.00186	0.0093	CbGeAlD
Thioridazine—Vomiting—Melphalan—ovarian cancer	0.00185	0.00267	CcSEcCtD
Thioridazine—Rash—Melphalan—ovarian cancer	0.00184	0.00265	CcSEcCtD
Thioridazine—Dermatitis—Melphalan—ovarian cancer	0.00184	0.00265	CcSEcCtD
Thioridazine—Arrhythmia—Docetaxel—ovarian cancer	0.00183	0.00263	CcSEcCtD
Thioridazine—KCNH2—lymph node—ovarian cancer	0.0018	0.00898	CbGeAlD
Thioridazine—Mental disorder—Docetaxel—ovarian cancer	0.00179	0.00258	CcSEcCtD
Thioridazine—Erythema—Docetaxel—ovarian cancer	0.00178	0.00256	CcSEcCtD
Thioridazine—Nausea—Topotecan—ovarian cancer	0.00177	0.00255	CcSEcCtD
Thioridazine—Cardiac arrest—Doxorubicin—ovarian cancer	0.00175	0.00253	CcSEcCtD
Thioridazine—Diarrhoea—Vinorelbine—ovarian cancer	0.00174	0.00251	CcSEcCtD
Thioridazine—Nausea—Melphalan—ovarian cancer	0.00173	0.00249	CcSEcCtD
Thioridazine—Confusional state—Paclitaxel—ovarian cancer	0.00173	0.00249	CcSEcCtD
Thioridazine—Asthma—Epirubicin—ovarian cancer	0.00172	0.00248	CcSEcCtD
Thioridazine—Oedema—Paclitaxel—ovarian cancer	0.00171	0.00247	CcSEcCtD
Thioridazine—CYP2D6—female gonad—ovarian cancer	0.00171	0.00852	CbGeAlD
Thioridazine—Eosinophilia—Epirubicin—ovarian cancer	0.00171	0.00246	CcSEcCtD
Thioridazine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00168	0.00242	CcSEcCtD
Thioridazine—Tachycardia—Paclitaxel—ovarian cancer	0.00167	0.00241	CcSEcCtD
Thioridazine—HTR2A—testis—ovarian cancer	0.00166	0.0083	CbGeAlD
Thioridazine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00166	0.00239	CcSEcCtD
Thioridazine—Anaemia—Docetaxel—ovarian cancer	0.00164	0.00237	CcSEcCtD
Thioridazine—Pancytopenia—Epirubicin—ovarian cancer	0.00164	0.00236	CcSEcCtD
Thioridazine—Anorexia—Paclitaxel—ovarian cancer	0.00163	0.00235	CcSEcCtD
Thioridazine—Vomiting—Vinorelbine—ovarian cancer	0.00162	0.00233	CcSEcCtD
Thioridazine—Rash—Vinorelbine—ovarian cancer	0.00161	0.00231	CcSEcCtD
Thioridazine—Dermatitis—Vinorelbine—ovarian cancer	0.0016	0.00231	CcSEcCtD
Thioridazine—Hypotension—Paclitaxel—ovarian cancer	0.0016	0.00231	CcSEcCtD
Thioridazine—Headache—Vinorelbine—ovarian cancer	0.0016	0.0023	CcSEcCtD
Thioridazine—Asthma—Doxorubicin—ovarian cancer	0.00159	0.0023	CcSEcCtD
Thioridazine—Leukopenia—Docetaxel—ovarian cancer	0.00159	0.00229	CcSEcCtD
Thioridazine—Eosinophilia—Doxorubicin—ovarian cancer	0.00158	0.00227	CcSEcCtD
Thioridazine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00157	0.00226	CcSEcCtD
Thioridazine—Weight increased—Epirubicin—ovarian cancer	0.00157	0.00226	CcSEcCtD
Thioridazine—Drowsiness—Epirubicin—ovarian cancer	0.00154	0.00221	CcSEcCtD
Thioridazine—Somnolence—Paclitaxel—ovarian cancer	0.00152	0.00219	CcSEcCtD
Thioridazine—CYP2D6—testis—ovarian cancer	0.00151	0.00756	CbGeAlD
Thioridazine—Pancytopenia—Doxorubicin—ovarian cancer	0.00151	0.00218	CcSEcCtD
Thioridazine—Nausea—Vinorelbine—ovarian cancer	0.00151	0.00218	CcSEcCtD
Thioridazine—Jaundice—Epirubicin—ovarian cancer	0.0015	0.00216	CcSEcCtD
Thioridazine—Decreased appetite—Paclitaxel—ovarian cancer	0.00149	0.00215	CcSEcCtD
Thioridazine—Constipation—Paclitaxel—ovarian cancer	0.00147	0.00211	CcSEcCtD
Thioridazine—Confusional state—Docetaxel—ovarian cancer	0.00146	0.00211	CcSEcCtD
Thioridazine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00145	0.0021	CcSEcCtD
Thioridazine—Oedema—Docetaxel—ovarian cancer	0.00145	0.00209	CcSEcCtD
Thioridazine—Weight increased—Doxorubicin—ovarian cancer	0.00145	0.00209	CcSEcCtD
Thioridazine—HRH1—lymph node—ovarian cancer	0.00144	0.0072	CbGeAlD
Thioridazine—Agranulocytosis—Epirubicin—ovarian cancer	0.00143	0.00206	CcSEcCtD
Thioridazine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00142	0.00205	CcSEcCtD
Thioridazine—Drowsiness—Doxorubicin—ovarian cancer	0.00142	0.00205	CcSEcCtD
Thioridazine—Tachycardia—Docetaxel—ovarian cancer	0.00142	0.00204	CcSEcCtD
Thioridazine—ADRA2A—lymph node—ovarian cancer	0.00142	0.00707	CbGeAlD
Thioridazine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00141	0.00203	CcSEcCtD
Thioridazine—Jaundice—Doxorubicin—ovarian cancer	0.00139	0.00199	CcSEcCtD
Thioridazine—Anorexia—Docetaxel—ovarian cancer	0.00138	0.00199	CcSEcCtD
Thioridazine—Oedema peripheral—Epirubicin—ovarian cancer	0.00136	0.00196	CcSEcCtD
Thioridazine—Hypotension—Docetaxel—ovarian cancer	0.00136	0.00195	CcSEcCtD
Thioridazine—Body temperature increased—Paclitaxel—ovarian cancer	0.00135	0.00195	CcSEcCtD
Thioridazine—Agranulocytosis—Doxorubicin—ovarian cancer	0.00133	0.00191	CcSEcCtD
Thioridazine—Somnolence—Docetaxel—ovarian cancer	0.00129	0.00186	CcSEcCtD
Thioridazine—Decreased appetite—Docetaxel—ovarian cancer	0.00126	0.00182	CcSEcCtD
Thioridazine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00126	0.00182	CcSEcCtD
Thioridazine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00126	0.00181	CcSEcCtD
Thioridazine—Constipation—Docetaxel—ovarian cancer	0.00124	0.00179	CcSEcCtD
Thioridazine—Arrhythmia—Epirubicin—ovarian cancer	0.00123	0.00177	CcSEcCtD
Thioridazine—Mental disorder—Epirubicin—ovarian cancer	0.00121	0.00174	CcSEcCtD
Thioridazine—Erythema—Epirubicin—ovarian cancer	0.0012	0.00173	CcSEcCtD
Thioridazine—Feeling abnormal—Docetaxel—ovarian cancer	0.0012	0.00172	CcSEcCtD
Thioridazine—Diarrhoea—Paclitaxel—ovarian cancer	0.00117	0.00169	CcSEcCtD
Thioridazine—Body temperature increased—Docetaxel—ovarian cancer	0.00115	0.00165	CcSEcCtD
Thioridazine—Arrhythmia—Doxorubicin—ovarian cancer	0.00114	0.00164	CcSEcCtD
Thioridazine—Vision blurred—Epirubicin—ovarian cancer	0.00113	0.00163	CcSEcCtD
Thioridazine—Mental disorder—Doxorubicin—ovarian cancer	0.00112	0.00161	CcSEcCtD
Thioridazine—Erythema—Doxorubicin—ovarian cancer	0.00111	0.0016	CcSEcCtD
Thioridazine—Anaemia—Epirubicin—ovarian cancer	0.00111	0.0016	CcSEcCtD
Thioridazine—Agitation—Epirubicin—ovarian cancer	0.0011	0.00159	CcSEcCtD
Thioridazine—Vomiting—Paclitaxel—ovarian cancer	0.00109	0.00157	CcSEcCtD
Thioridazine—Rash—Paclitaxel—ovarian cancer	0.00108	0.00156	CcSEcCtD
Thioridazine—Dermatitis—Paclitaxel—ovarian cancer	0.00108	0.00155	CcSEcCtD
Thioridazine—Leukopenia—Epirubicin—ovarian cancer	0.00107	0.00155	CcSEcCtD
Thioridazine—Headache—Paclitaxel—ovarian cancer	0.00107	0.00155	CcSEcCtD
Thioridazine—Hypersensitivity—Docetaxel—ovarian cancer	0.00107	0.00154	CcSEcCtD
Thioridazine—Vision blurred—Doxorubicin—ovarian cancer	0.00105	0.00151	CcSEcCtD
Thioridazine—Anaemia—Doxorubicin—ovarian cancer	0.00103	0.00148	CcSEcCtD
Thioridazine—Agitation—Doxorubicin—ovarian cancer	0.00102	0.00147	CcSEcCtD
Thioridazine—Nausea—Paclitaxel—ovarian cancer	0.00102	0.00147	CcSEcCtD
Thioridazine—Leukopenia—Doxorubicin—ovarian cancer	0.000994	0.00143	CcSEcCtD
Thioridazine—Diarrhoea—Docetaxel—ovarian cancer	0.000994	0.00143	CcSEcCtD
Thioridazine—Confusional state—Epirubicin—ovarian cancer	0.000988	0.00142	CcSEcCtD
Thioridazine—Oedema—Epirubicin—ovarian cancer	0.000979	0.00141	CcSEcCtD
Thioridazine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000959	0.00138	CcSEcCtD
Thioridazine—Tachycardia—Epirubicin—ovarian cancer	0.000956	0.00138	CcSEcCtD
Thioridazine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000947	0.00136	CcSEcCtD
Thioridazine—Anorexia—Epirubicin—ovarian cancer	0.000934	0.00134	CcSEcCtD
Thioridazine—Vomiting—Docetaxel—ovarian cancer	0.000923	0.00133	CcSEcCtD
Thioridazine—Rash—Docetaxel—ovarian cancer	0.000916	0.00132	CcSEcCtD
Thioridazine—Hypotension—Epirubicin—ovarian cancer	0.000915	0.00132	CcSEcCtD
Thioridazine—Dermatitis—Docetaxel—ovarian cancer	0.000915	0.00132	CcSEcCtD
Thioridazine—Confusional state—Doxorubicin—ovarian cancer	0.000914	0.00132	CcSEcCtD
Thioridazine—Headache—Docetaxel—ovarian cancer	0.00091	0.00131	CcSEcCtD
Thioridazine—Oedema—Doxorubicin—ovarian cancer	0.000906	0.00131	CcSEcCtD
Thioridazine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000887	0.00128	CcSEcCtD
Thioridazine—Tachycardia—Doxorubicin—ovarian cancer	0.000884	0.00127	CcSEcCtD
Thioridazine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000876	0.00126	CcSEcCtD
Thioridazine—Somnolence—Epirubicin—ovarian cancer	0.000871	0.00125	CcSEcCtD
Thioridazine—Anorexia—Doxorubicin—ovarian cancer	0.000864	0.00124	CcSEcCtD
Thioridazine—Nausea—Docetaxel—ovarian cancer	0.000863	0.00124	CcSEcCtD
Thioridazine—Decreased appetite—Epirubicin—ovarian cancer	0.000851	0.00123	CcSEcCtD
Thioridazine—Hypotension—Doxorubicin—ovarian cancer	0.000847	0.00122	CcSEcCtD
Thioridazine—Constipation—Epirubicin—ovarian cancer	0.000838	0.00121	CcSEcCtD
Thioridazine—Feeling abnormal—Epirubicin—ovarian cancer	0.000807	0.00116	CcSEcCtD
Thioridazine—Somnolence—Doxorubicin—ovarian cancer	0.000806	0.00116	CcSEcCtD
Thioridazine—Decreased appetite—Doxorubicin—ovarian cancer	0.000788	0.00113	CcSEcCtD
Thioridazine—Constipation—Doxorubicin—ovarian cancer	0.000775	0.00112	CcSEcCtD
Thioridazine—Body temperature increased—Epirubicin—ovarian cancer	0.000774	0.00112	CcSEcCtD
Thioridazine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000747	0.00108	CcSEcCtD
Thioridazine—Hypersensitivity—Epirubicin—ovarian cancer	0.000722	0.00104	CcSEcCtD
Thioridazine—Body temperature increased—Doxorubicin—ovarian cancer	0.000716	0.00103	CcSEcCtD
Thioridazine—Diarrhoea—Epirubicin—ovarian cancer	0.00067	0.000965	CcSEcCtD
Thioridazine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000668	0.000962	CcSEcCtD
Thioridazine—Vomiting—Epirubicin—ovarian cancer	0.000623	0.000897	CcSEcCtD
Thioridazine—Diarrhoea—Doxorubicin—ovarian cancer	0.00062	0.000893	CcSEcCtD
Thioridazine—Rash—Epirubicin—ovarian cancer	0.000618	0.000889	CcSEcCtD
Thioridazine—Dermatitis—Epirubicin—ovarian cancer	0.000617	0.000889	CcSEcCtD
Thioridazine—Headache—Epirubicin—ovarian cancer	0.000614	0.000884	CcSEcCtD
Thioridazine—Nausea—Epirubicin—ovarian cancer	0.000582	0.000838	CcSEcCtD
Thioridazine—Vomiting—Doxorubicin—ovarian cancer	0.000576	0.00083	CcSEcCtD
Thioridazine—Rash—Doxorubicin—ovarian cancer	0.000571	0.000823	CcSEcCtD
Thioridazine—Dermatitis—Doxorubicin—ovarian cancer	0.000571	0.000822	CcSEcCtD
Thioridazine—Headache—Doxorubicin—ovarian cancer	0.000568	0.000818	CcSEcCtD
Thioridazine—Nausea—Doxorubicin—ovarian cancer	0.000538	0.000775	CcSEcCtD
Thioridazine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.41e-05	0.000134	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—MYC—ovarian cancer	1.41e-05	0.000134	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.4e-05	0.000133	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	1.4e-05	0.000133	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	1.4e-05	0.000133	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	1.4e-05	0.000133	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	1.39e-05	0.000132	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—MAPK1—ovarian cancer	1.38e-05	0.000131	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—EGFR—ovarian cancer	1.38e-05	0.000131	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	1.38e-05	0.000131	CbGpPWpGaD
Thioridazine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.38e-05	0.000131	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	1.37e-05	0.00013	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—PTEN—ovarian cancer	1.37e-05	0.00013	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.37e-05	0.00013	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.37e-05	0.00013	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	1.37e-05	0.00013	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.36e-05	0.00013	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	1.36e-05	0.000129	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.36e-05	0.000129	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—IL2—ovarian cancer	1.36e-05	0.000129	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	1.35e-05	0.000129	CbGpPWpGaD
Thioridazine—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.35e-05	0.000129	CbGpPWpGaD
Thioridazine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.35e-05	0.000128	CbGpPWpGaD
Thioridazine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.35e-05	0.000128	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.35e-05	0.000128	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—TP53—ovarian cancer	1.34e-05	0.000128	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	1.34e-05	0.000128	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—TP53—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—IL2—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	1.33e-05	0.000126	CbGpPWpGaD
Thioridazine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	1.32e-05	0.000126	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.32e-05	0.000125	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CASP3—ovarian cancer	1.32e-05	0.000125	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—IL2—ovarian cancer	1.31e-05	0.000125	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.31e-05	0.000125	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	1.31e-05	0.000125	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	1.31e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.31e-05	0.000124	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—IL6—ovarian cancer	1.31e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.3e-05	0.000124	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	1.3e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.3e-05	0.000124	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.3e-05	0.000124	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.3e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.3e-05	0.000123	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.3e-05	0.000123	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.29e-05	0.000123	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.29e-05	0.000123	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.29e-05	0.000122	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.29e-05	0.000122	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.29e-05	0.000122	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.29e-05	0.000122	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—HRAS—ovarian cancer	1.28e-05	0.000122	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	1.28e-05	0.000122	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.28e-05	0.000122	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.28e-05	0.000121	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.27e-05	0.000121	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	1.27e-05	0.00012	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.27e-05	0.00012	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.27e-05	0.00012	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.27e-05	0.00012	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.26e-05	0.00012	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.26e-05	0.00012	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.26e-05	0.000119	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—PTEN—ovarian cancer	1.26e-05	0.000119	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.26e-05	0.000119	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.25e-05	0.000119	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	0.000119	CbGpPWpGaD
Thioridazine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.25e-05	0.000119	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.25e-05	0.000118	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	0.000118	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	1.24e-05	0.000117	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Thioridazine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—IL6—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.23e-05	0.000116	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.22e-05	0.000116	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.22e-05	0.000116	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.21e-05	0.000115	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.21e-05	0.000115	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	1.21e-05	0.000115	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.21e-05	0.000114	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.2e-05	0.000114	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.2e-05	0.000114	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.2e-05	0.000114	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.19e-05	0.000113	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	1.19e-05	0.000113	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.19e-05	0.000113	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.19e-05	0.000113	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—TP53—ovarian cancer	1.16e-05	0.00011	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.16e-05	0.00011	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	1.15e-05	0.00011	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.15e-05	0.000109	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.15e-05	0.000109	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.14e-05	0.000109	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.14e-05	0.000108	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.14e-05	0.000108	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.14e-05	0.000108	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.14e-05	0.000108	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.14e-05	0.000108	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—AKT1—ovarian cancer	1.13e-05	0.000108	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	0.000107	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	0.000107	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.13e-05	0.000107	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.12e-05	0.000107	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.12e-05	0.000107	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.12e-05	0.000107	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.12e-05	0.000106	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.12e-05	0.000106	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.12e-05	0.000106	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	1.12e-05	0.000106	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.11e-05	0.000106	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.11e-05	0.000106	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.11e-05	0.000105	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	1.11e-05	0.000105	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	1.1e-05	0.000105	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.1e-05	0.000105	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.1e-05	0.000104	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.09e-05	0.000104	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PTEN—ovarian cancer	1.09e-05	0.000103	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.08e-05	0.000102	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.07e-05	0.000102	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.07e-05	0.000101	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MYC—ovarian cancer	1.06e-05	0.000101	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—IL6—ovarian cancer	1.06e-05	0.000101	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	1.06e-05	0.0001	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.05e-05	0.0001	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.05e-05	9.94e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.04e-05	9.91e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.04e-05	9.88e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.04e-05	9.88e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.03e-05	9.83e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.03e-05	9.81e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.03e-05	9.76e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MYC—ovarian cancer	1.03e-05	9.76e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.02e-05	9.73e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.02e-05	9.73e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.02e-05	9.73e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.02e-05	9.72e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.02e-05	9.72e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.02e-05	9.71e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.02e-05	9.7e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.02e-05	9.7e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.02e-05	9.7e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	1.01e-05	9.54e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	1.01e-05	9.54e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1e-05	9.53e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1e-05	9.52e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1e-05	9.52e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—TP53—ovarian cancer	9.95e-06	9.45e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—TP53—ovarian cancer	9.9e-06	9.4e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—KRAS—ovarian cancer	9.83e-06	9.33e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	9.79e-06	9.3e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	9.79e-06	9.29e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—AKT1—ovarian cancer	9.77e-06	9.28e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PTEN—ovarian cancer	9.71e-06	9.22e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	9.67e-06	9.18e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	9.67e-06	9.18e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—KRAS—ovarian cancer	9.65e-06	9.16e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	9.52e-06	9.04e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	9.52e-06	9.03e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	9.5e-06	9.01e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	9.48e-06	9e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	9.47e-06	8.99e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	9.47e-06	8.99e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	9.32e-06	8.84e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	9.31e-06	8.84e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—IL6—ovarian cancer	9.11e-06	8.65e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	9.06e-06	8.6e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—IL6—ovarian cancer	9.06e-06	8.6e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	9.03e-06	8.57e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PTEN—ovarian cancer	8.93e-06	8.48e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	8.88e-06	8.43e-05	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—PIK3CA—ovarian cancer	8.88e-06	8.43e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	8.87e-06	8.42e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PTEN—ovarian cancer	8.85e-06	8.4e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	8.8e-06	8.35e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	8.75e-06	8.31e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—TP53—ovarian cancer	8.74e-06	8.29e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	8.72e-06	8.28e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	8.7e-06	8.26e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	8.67e-06	8.23e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—TP53—ovarian cancer	8.6e-06	8.16e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—TP53—ovarian cancer	8.58e-06	8.14e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—TP53—ovarian cancer	8.44e-06	8.01e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	8.42e-06	7.99e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	8.4e-06	7.98e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	8.36e-06	7.94e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—HRAS—ovarian cancer	8.35e-06	7.93e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	8.22e-06	7.8e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—HRAS—ovarian cancer	8.2e-06	7.79e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	8.08e-06	7.67e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	8.07e-06	7.66e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	8.05e-06	7.64e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	8e-06	7.6e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—IL6—ovarian cancer	8e-06	7.59e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—AKT1—ovarian cancer	7.9e-06	7.5e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—IL6—ovarian cancer	7.87e-06	7.47e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—IL6—ovarian cancer	7.85e-06	7.45e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	7.82e-06	7.42e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—IL6—ovarian cancer	7.72e-06	7.33e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	7.7e-06	7.31e-05	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	7.67e-06	7.28e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PTEN—ovarian cancer	7.56e-06	7.18e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	7.48e-06	7.1e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—AKT1—ovarian cancer	7.38e-06	7e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	7.26e-06	6.89e-05	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—AKT1—ovarian cancer	7.25e-06	6.88e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—AKT1—ovarian cancer	7.24e-06	6.88e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	7.16e-06	6.8e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	7.13e-06	6.77e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	7.11e-06	6.75e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	6.85e-06	6.5e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	6.6e-06	6.27e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.3e-06	5.98e-05	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—AKT1—ovarian cancer	6.27e-06	5.95e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	6.24e-06	5.93e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—AKT1—ovarian cancer	5.59e-06	5.31e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.34e-06	5.07e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—AKT1—ovarian cancer	5.15e-06	4.89e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—AKT1—ovarian cancer	5.1e-06	4.84e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—AKT1—ovarian cancer	4.36e-06	4.14e-05	CbGpPWpGaD
